BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 177 filers reported holding BLUEBIRD BIO INC in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,115 | +15.8% | 34,906 | +25.3% | 0.00% | – |
| Q2 2023 | $91,614 | -1.3% | 27,847 | -4.7% | 0.00% | – |
| Q1 2023 | $92,859 | -77.6% | 29,231 | -51.3% | 0.00% | -100.0% |
| Q4 2022 | $415,388 | +196.7% | 60,083 | +170.5% | 0.00% | – |
| Q3 2022 | $140,000 | +57.3% | 22,208 | +3.8% | 0.00% | – |
| Q2 2022 | $89,000 | -95.2% | 21,387 | -1.3% | 0.00% | -100.0% |
| Q1 2022 | $1,871,000 | +939.4% | 21,676 | +20.0% | 0.00% | – |
| Q4 2021 | $180,000 | -35.0% | 18,058 | +24.4% | 0.00% | -100.0% |
| Q3 2021 | $277,000 | -29.2% | 14,515 | +18.4% | 0.00% | 0.0% |
| Q2 2021 | $391,000 | +9.8% | 12,256 | +4.1% | 0.00% | 0.0% |
| Q1 2021 | $356,000 | -25.1% | 11,778 | +7.3% | 0.00% | 0.0% |
| Q4 2020 | $475,000 | -14.9% | 10,979 | +4.5% | 0.00% | -50.0% |
| Q3 2020 | $558,000 | +6.3% | 10,503 | +23.3% | 0.00% | 0.0% |
| Q2 2020 | $525,000 | +37.1% | 8,520 | +2.7% | 0.00% | 0.0% |
| Q1 2020 | $383,000 | – | 8,298 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
| Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
| PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
| Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
| Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
| Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
| Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
| Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
| Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
| Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |